Pfizer and Blackstone agree to up to $1.5B for obesity drug development
Pfizer and Blackstone Life Sciences announced on November 11, 2026, a funding agreement worth up to $1.5B for developing Pfizer’s investigational obesity treatment berobenatide. Blackstone-managed funds will cover development costs through 2028, while payments to Blackstone depend on U.S. regulatory approval and commercial sales milestones. Pfizer retains control and ownership of the program.
Why it matters
The agreement shifts part of berobenatide’s development funding to Blackstone while allowing Pfizer to retain control of the drug. Pfizer also remains responsible for milestone payments if the treatment meets the stated regulatory and commercial conditions.
Key facts
- 1The agreement provides Pfizer with up to $1.5B in development funding for berobenatide. tradingview.com
- 2Blackstone-managed funds will support the program through 2028. tradingview.com
- 3Milestone payments depend on U.S. regulatory approval and commercial sales targets. tradingview.com
- 4Berobenatide is being developed as a monthly GLP-1 receptor agonist peptide for chronic weight management and obesity-related conditions. finance.yahoo.com
- 5Pfizer retains full control and ownership of berobenatide. tradingview.com
Summary written by AlphAI AI Desk from 20 of 20 sources. Not investment advice. Figures are as stated by the linked sources.